Navigation Links
Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets

Longer Term Growth of Diabetic Neuropathy Market Will Be Driven by Launches of Disease-Modifying Therapies, According to a New Report from Decision


WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2016 Genentech/Roche's Lucentis and Eli Lilly's ruboxistaurin will drive the markets for the treatment of diabetic retinopathy and diabetic nephropathy.

The new Pharmacor report entitled Diabetic Complications: Retinopathy, Neuropathy, and Nephropathy finds that, over the next decade, treatment of diabetic complications will expand considerably beyond tight control of blood pressure and glucose levels. Lucentis and ruboxistaurin will come the closest to achieving blockbuster status as treatments for diabetic complications in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additionally, although promising drug classes with potential disease-modifying activity that include PKC inhibitors and aldose reductase inhibitors have suffered a decade of setbacks and disappointing efficacy data, the report finds that longer-term market growth will be driven by several of these novel therapies.

Therapies for the painful symptoms of diabetic neuropathy will continue to dominate sales, and few patients suffering non-painful diabetic neuropathy will receive treatment until the launches of disease-modifying therapies near the midpoint of the 2006-2016 forecast period.

"The diabetic neuropathy market will experience growth during the second half of our study period because of increasing use of Pfizer's antiepileptic drug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which are both approved specifically for the treatment of diabetic neuropathic pain," said Donny Wong, Ph.D., analyst at Decision Resources. "Longer term growth will also be driven by the launch of novel disease-modifying therapies such as Dainippon/Eisai/Kyorin's ranirestat and Sangamo Biosciences' SB-509."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approval For Lucentis
2. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
3. Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy
4. Sleepy drivers increase road death toll
5. Traffic Violations Result in Safer Drivers
6. Dyslexia may slow a drivers reaction time as much as moderate drinking!!
7. Study suggests symptom driven therapy for adults with asthma
8. Peppermint or cinnamon smell can make drivers more alert
9. Mechanical forces drive early heart development
10. Measles Vaccination Drive Intensified In Quake-Hit Pakistan
11. More Funds Are Required For Immunisation Drive
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
Breaking Medicine Technology: